Philadelphia, 12 - 13 November 2024
Schedule
Create your personal agenda –check the favourite icon
Nov 129:00
Conference pass
Opening Remarks: Sven Kili, Chief Development Officerm CCRM & Principal, Sven Kili Consulting
Keynotes
Sven Kili, CDO, CCRM
Keynote Theatre
Nov 129:05
Conference pass
Cell and Gene State of the Industry Address: Looking at 2024 and Beyond
Keynotes
Sven Kili, CDO, CCRM
P.J. Brooks, Acting Director, National Institutes of Health
Kinnari Patel, President, COO, Rocket Pharma
Amy Nicole Nayar, Vice President of U.S. Patient Advocacy & Government Affairs, Novartis Gene Therapies
Steven Kelly, President And Chief Executive Officer, Carisma Therapeutics
Keynote Theatre
Nov 1210:05
Conference pass
Fireside chat with Laurie Adami, CAR-T Patient and Cindy Perettie, EVP, Kite Pharma
Keynotes
Moderator: Cindy Perettie, CEO, Kite Pharma
Keynote Theatre
Nov 1210:45
Conference pass
CAR expression during lentivirus production? why it’s a problem and how to address it
Start-up Pitch
Seminar Theatre, Expo Floor
Nov 1211:00
Conference pass
VirCAD: an HPC-enabled platform for viral bioengineering
Start-up Pitch
Stefan Lukianov, Chief Executive Officer, Salve Therapeutics
Seminar Theatre, Expo Floor
Nov 1211:15
Conference pass
Improving Global CAR-T Accessibility through Optimized Manufacturing Processes
Start-up Pitch
Seminar Theatre, Expo Floor
Nov 1211:30
Conference pass
Roundtable 1: The opportunities and challenges of moving cell therapy to gene therapy
Keynotes
David Peritt, CSO, Lupagen
Keynote Theatre
Nov 1211:30
Conference pass
Roundtable 10 How can industry do better to partner with patients?
Keynotes
Melissa Penn, Director Patient Engagement Research & Development, Bayer
Keynote Theatre
Nov 1211:30
Conference pass
Roundtable 10: How can industry do better to partner with patients?
Keynotes
Melissa Penn, Director Patient Engagement Research & Development, Bayer
Keynote Theatre
Nov 1211:30
Conference pass
Roundtable 2: Is Industry ready to manufacture greater than a million patients/year if solid tumor approved
Keynotes
Keynote Theatre
Nov 1211:30
Conference pass
Roundtable 3: Mitigation Strategies for Immune Response to AAV Gene Therapy
Keynotes
Klaudia Kuranda, Head of Immunology, Indpendent
Keynote Theatre
Nov 1211:30
Conference pass
Roundtable 4: Scaling up to commercial level
Keynotes
Angela Columbano, Head of Business Development, GENETHON
Keynote Theatre
Nov 1211:30
Conference pass
Roundtable 5: How to prepare for interactions with regulators
Keynotes
Margareth Jorvid, Head of Regulatory Affairs, Ilya Pharma
Keynote Theatre
Nov 1211:30
Conference pass
Roundtable 7: Strategies for Fundraising
Keynotes
Stephen Sullivan, COO, iPSirius
Keynote Theatre
Nov 1211:30
Conference pass
Roundtable 8: CMC manufacturing challenges: autologous vs. allogeneic
Keynotes
Lavanya Peddada, Sr Dir., Process Development, Vittoria Biotherapeutics
Keynote Theatre
Nov 1211:30
Conference pass
Roundtable 9: Envisioning better business models for ultra-rare disease treatments
Keynotes
Craig Martin, Founder, CEO, Orphan Therapeutics Accelerator
Keynote Theatre
Nov 1212:30
Conference pass
Novel Expanded AAV Gene Therapy Platform
Start-up Pitch
Brian Hetrick, Chief Executive Officer, Virongy Biosciences Inc
Seminar Theatre, Expo Floor
Nov 1212:45
Conference pass
Topic TBC
Start-up Pitch
Krisha Patel, Co-founder, Assurea LLC
Seminar Theatre, Expo Floor
Nov 1213:00
Conference pass
Cell Bridge Strategies – Bridging Science to Business for Regenerative Medicine & Advanced Therapy Companies
Start-up Pitch
Jane Andrews, Chief Executive Officer & Founder, Cell Bridge Strategies, LLC
Seminar Theatre, Expo Floor
Nov 1213:15
Conference pass
Topic TBC
Start-up Pitch
Harsh Bhuta, Senior Product Manager, CellRev
Seminar Theatre, Expo Floor
Nov 1213:29
Conference pass
Chair: Gregory Fiore, Chief Executive Officer, Exacis Biotherapeutics
Track 1: Cell Therapy
Gregory Fiore, CEO, Exacis Biotherapeutics
Keynote Theatre
Nov 1213:29
Conference pass
Chair: David Morrow, Scientific Program Manager, EATRIS
Track 2: Innovation Showcase
David Morrow, Scientist, EATRIS
Seminar Theatre, Expo Floor
Nov 1213:29
Conference pass
Chair: Betsy Lahue, Co-Founder & CEO, Alkemi
Track 3: Evidence, Pricing & Access
120A
Nov 1213:29
Conference pass
Chair: Xiao Huang, Assistant Professor, Drexel University
Track 4: Gene Modified Cell Therapy
120B
Nov 1213:29
Conference pass
Chair: Susan Brisendine, Director, Patient Advocacy, Bluebird Bio
Track 5: Gene Therapy
Susan Brisendine, Director, Patient Advocacy, Bluebird Bio
120C
Nov 1213:29
Conference pass
Chair: Patrick Hanley, Chief and Director of Cell Therapy Program, Children’s National Hospital
Track 6: Cell Therapy Manufacture (Sponsored by Terumo BCT)
Patrick Hanley, Chief, Children's National Medical Center
121A
Nov 1213:29
Conference pass
Chair: Howard Wu, Co-Founder & Chief Scientific Officer, Full Circles Therapeutics
Track 7: Viral Vector Manufacture
121 B
Nov 1213:29
Conference pass
Chair: Yossi Schwartz, Director, Transfusion Services, Moffitt Cancer Center
Track 8: Supply Chain & Logistics
Yossi Schwartz, Director, Transfusion Services, Moffitt Cancer Center
121 C
Nov 1213:30
Conference pass
Allogeneic CAR T Cell Therapies: Ushering in the Next Wave of Innovation
Track 1: Cell Therapy
Christina Pham, Director, Preclinical Science, Atara Biotherapeutics
Keynote Theatre
Nov 1213:30
Conference pass
Driving forward new cell therapies for blood cancer since 1949: The Leukemia & Lymphoma Society
Track 2: Innovation Showcase
Seminar Theatre, Expo Floor
Nov 1213:30
Conference pass
Panel: Alternate Pricing Models and Outcome-based agreements
Track 3: Evidence, Pricing & Access
Erica Cischke, VP, Government Affairs, Alliance for Regenerative Medicine
Andrew York, Executive Director, Maryland Prescription Drug Affordability Board
120A
Nov 1213:30
Conference pass
Democratizing gene modified cell therapy for neurodegenerative diseases
Track 4: Gene Modified Cell Therapy
Samarendra Mohanty, Founder-President, Chief Scientific Officer, Nanoscope Therapeutics
120B
Nov 1213:30
Conference pass
Platform Vector Gene Therapy Pilot (PaVe-GT) Project
Track 5: Gene Therapy
P.J. Brooks, Acting Director, National Institutes of Health
120C
Nov 1213:30
Conference pass
Global quality standardization to streamline the development of cell therapies
Track 6: Cell Therapy Manufacture (Sponsored by Terumo BCT)
Stephan Krause, Executive Director, Bristol Myers Squibb
121A
Nov 1213:30
Conference pass
Quality Challenges in Taking Gene Therapy to the Masses
Track 7: Viral Vector Manufacture
Sarah Thomas, VP Quality, REGENXBIO
121 B
Nov 1213:30
Conference pass
Carsgen Therapeutics Case study
Track 8: Supply Chain & Logistics
Jie Jia, VP Strategic Alliances, Carsgen Therapeutics
121 C
Nov 1213:50
Conference pass
Small-scale bioreactor system for process development of regenerative stem cell therapies
Track 1: Cell Therapy
Keynote Theatre
Nov 1213:50
Conference pass
Learnings from the Rare Disease Innovations Institute
Track 2: Innovation Showcase
Tara Britt, Founder and President, Rare Disease Innovations Institute, Inc.
Seminar Theatre, Expo Floor
Nov 1213:50
Conference pass
Ending the devastation caused by genetic and other severe diseases through HSC gene therapy and newborn screening: A case study in metachromatic leukodystrophy
Track 4: Gene Modified Cell Therapy
Leslie Meltzer, CMO, Orchard Therapeutics
120B
Nov 1213:50
Conference pass
Right place, right time: challenges in targeting and new modalities for delivery
Track 5: Gene Therapy
Moderator: Sean Armour, SVP, Head of Discovery, Spark Therapeutics
Zhenghong Gao, Head of Non-Viral Delivery, Asklepios BioPharmaceutical, Inc.
120C
Nov 1213:50
Conference pass
Beyond Promise: A Demonstrated, End-to-End CAR-T Manufacturing Platform Key Objectives
Track 6: Cell Therapy Manufacture (Sponsored by Terumo BCT)
- Unlock your therapy's potential with true end-to-end manufacturing – including collections
- Review of the latest unmodified T cell and CAR-T cell expansion data with some of the lowest initial seed densities from an automated platform
- Comparison of hollow-fiber bioreactor technology to other commercial manufacturing options
Mindy Miller, Manager, Senior Scientist, Terumo BCT
121A
Nov 1213:50
Conference pass
Potency Assay Development for Gene Therapies
Track 7: Viral Vector Manufacture
Andrea Sobjak, Director, VV Analytics, Johnson and Johnson Innovative Medicine
121 B
Nov 1213:50
Conference pass
Handling the different requirements for commercial and investigational MNC collections by apheresis
Track 8: Supply Chain & Logistics
Aleh (Oleg) Bobr, Medical Director, University of Nebraska Medical Center
121 C
Nov 1214:10
Conference pass
Novel approaches to genetic engineering and cell-type specific therapeutic applications
Track 1: Cell Therapy
Kate Rochlin, COO, in8bio
Keynote Theatre
Nov 1214:10
Conference pass
The Patient Journey through Drug Development leading to Creativity, Innovation and Startups
Track 2: Innovation Showcase
Allyson Berent, Chief Science Officer, Foundation for Angelman Syndrome Therapeutics
Seminar Theatre, Expo Floor
Nov 1214:10
Conference pass
Novel Advanced Patient Partnerships for Reimbursement of Novel Advanced Therapies
Track 3: Evidence, Pricing & Access
120A
Nov 1214:10
Conference pass
In-vivo generation of therapeutic cells CAR-T and beyond
Track 4: Gene Modified Cell Therapy
David Peritt, CSO, Lupagen
120B
Nov 1214:10
Conference pass
Navigating the Logistics and Economics of Externally Manufactured Cell Therapies
Track 6: Cell Therapy Manufacture (Sponsored by Terumo BCT)
Tim Wiltshire, Section Director, IMPACT Lab, Mayo Clinic
121A
Nov 1214:10
Conference pass
Establishing a pioneering facility to support viral vector manufacturing
Track 7: Viral Vector Manufacture
121 B
Nov 1214:30
Conference pass
Enhancing cell and gene therapy manufacturing processes by in-line, on-line and at-line bioprocess analytical technologies
Track 2: Innovation Showcase
Delivering patients with safe and effective therapies requires robust and scalable manufacturing processes. In cell therapies (CT), ensuring consistent and scalable cell expansion can prevent deviations in product quality and thus improve treatment outcomes in patients. In gene therapies (GT), scalable processes are imperative for improving and sustaining high viral vector productivity.
Growing demand for CT and GT necessitates the development of more efficient, robust, and larger yield processes. This calls for real-time monitoring and frequent at-line information of process parameters that impact cell growth and health. In addition, controlling nutrient (e.g., glucose and amino acid) levels to avoid the accumulation of toxic metabolites (eg. lactate), is key. Monitoring sufficient depth and breadth of process parameters provides invaluable insights into the metabolic state of cell cultures, enabling control to optimize, and enhance manufacturing robustness. Many current process parameter measurements are informative, but labor-intensive, and some are too slow to be actionable in processes. Technologies for real-time and at-line bioprocess characterization have rapidly advanced in recent years to be easily deployable in different types of cell culture conditions and bioreactors.
We show solutions for both CT and GT:
- Process analytical technologies, at-line and real-time monitoring and control, pioneering strategies designed to address the challenges associated with CT and GT manufacturing.
- Process monitoring and control to increase process knowledge and enable data-driven process development and optimization for improved therapy outcomes.
Seminar Theatre, Expo Floor
Nov 1214:30
Conference pass
Leveraging real-world evidence to facilitate patient access
Track 3: Evidence, Pricing & Access
Moderator: Nneka Onwudiwe, Former Regulatory Officer, Food and Drug Administration (FDA)
Melissa Penn, Director Patient Engagement Research & Development, Bayer
Jason Lott, VP, Global Evidence Generation, Bayer
120A
Nov 1214:30
Conference pass
Mechanisms of gene editing & gene delivery in complex cellular products
Track 4: Gene Modified Cell Therapy
Elena Peletskaya, Senior Scientific Director, Bristol-Myers Squibb
120B
Nov 1214:30
Conference pass
Navigating Regulatory Challenges for the Development and Approval of Gene Therapy Products
Track 5: Gene Therapy
120C
Nov 1214:30
Conference pass
Supply chain and logistics of off the shelf cell therapies
Track 8: Supply Chain & Logistics
Amanda Conerty, Executive Director, Artiva Biotherapeutics
121 C
Nov 1214:50
Conference pass
Cell and Gene Therapy for Neurologic Disorders
Track 1: Cell Therapy
Paul Orchard, Professor, University of Minnesota
Keynote Theatre
Nov 1214:50
Conference pass
The role of EATRIS in developing the next generation of Cell and Gene Therapies
Track 2: Innovation Showcase
David Morrow, Scientist, EATRIS
Seminar Theatre, Expo Floor
Nov 1214:50
Conference pass
Carisma Therapeutics Pipeline Update
Track 4: Gene Modified Cell Therapy
Michael Klichinsky, Co-Founder, Vice President Of Discovery And Research, Carisma Therapeutics
120B
Nov 1214:50
Conference pass
Advancing gene therapies for cardiomyopathy
Track 5: Gene Therapy
Kathryn Ivey, VP, Gene Therapy Research, Tenaya Therapeutics
120C
Nov 1214:50
Conference pass
Phase-Appropriate Automation Strategy for Cell Therapy
Track 6: Cell Therapy Manufacture (Sponsored by Terumo BCT)
Raymond Luke, Director, MSAT, Verismo Therapeutics
121A
Nov 1214:50
Conference pass
Lentiviral Vector Manufacturing’s Dirty Secrets
Track 7: Viral Vector Manufacture
121 B
Nov 1215:10
Conference pass
A different approach to cell therapy in Parkinson’s Disease
Track 1: Cell Therapy
Keynote Theatre
Nov 1215:10
Conference pass
Panel discussion: Reimbursement challenges in delivering cures
Track 3: Evidence, Pricing & Access
Andrew York, Executive Director, Maryland Prescription Drug Affordability Board
120A
Nov 1215:10
Conference pass
Creating robust and standardized assays to measure potency
Track 4: Gene Modified Cell Therapy
Jie Wei, Director, Bioanalytical Sciences, Tr1x, Inc
120B
Nov 1215:10
Conference pass
Novel gene therapies for retina disorders and Inherited rare disease
Track 5: Gene Therapy
120C
Nov 1215:10
Conference pass
Innovations in Potency Assay Development for Advanced Therapies
Track 6: Cell Therapy Manufacture (Sponsored by Terumo BCT)
121A
Nov 1215:10
Conference pass
Working towards a standardized future for supply chain in cell and gene therapy
Track 8: Supply Chain & Logistics
Moderator: Karishma Contractor, Senior Manager, Vertex pharmaceuticals
Aleh (Oleg) Bobr, Medical Director, University of Nebraska Medical Center
Lizette Caballero, Associate Director, Johnson & Johnson Pharmaceutical R&D
Yossi Schwartz, Director, Transfusion Services, Moffitt Cancer Center
121 C
Nov 1215:30
Conference pass
Selecting a CDMO with the patient’s needs in mind
Track 1: Cell Therapy
Jacqueline Stief, Head of Quality and Compliance, Verismo Therapeutics
Keynote Theatre
Nov 1215:30
Conference pass
Addressing the skills shortage in ATMPs
Track 2: Innovation Showcase
Moderator: David Morrow, Scientist, EATRIS
Craig Hasilo, CSO, Canadian Advanced Therapies Training Institute
ANGELA JUSTICE, Chief People Officer, Justice Group Advisors
Allen Horton, Head of Extl Manufacturing, Beam Therapeutics
Seminar Theatre, Expo Floor
Nov 1215:30
Conference pass
New frontiers in cell therapy: In-vivo engineering
Track 4: Gene Modified Cell Therapy
Moderator: David Peritt, CSO, Lupagen
Hamideh Parhiz, Assistant Professor, University of Pennsylvania
Phil Johnson, President, CEO, Interius BioTherapeutics, Inc.
120B
Nov 1215:30
Conference pass
Genethon – update on pre-clinical and clinical pipeline
Track 5: Gene Therapy
Angela Columbano, Head of Business Development, GENETHON
120C
Nov 1215:30
Conference pass
Staying agile and embracing technological innovations to optimize cell therapy manufacturing
Track 6: Cell Therapy Manufacture (Sponsored by Terumo BCT)
Moderator: Lior Raviv (ליאור רביב), CTO, Pluri
Raymond Luke, Director, MSAT, Verismo Therapeutics
Dan Bednarik, Chief Technology Officer, Black Canyon Bio
121A
Nov 1215:30
Conference pass
Demonstrating comparability to support regulatory approval
Track 7: Viral Vector Manufacture
Moderator: Clayton Beard, CSO and Site Head, BridgeBio Gene Therapy
Khandan Baradaran, Ph.D., SVP Regulatory and Quality, Nanoscope Therapeutics
121 B
Nov 1215:50
Conference pass
Generating a functional human thymus
Track 1: Cell Therapy
Holger Russ, Associate Professor, University of florida
Keynote Theatre
Nov 1215:50
Conference pass
Innovation in cardiovascular and neurological gene therapies
Track 5: Gene Therapy
Laura Richman, Chief Development Officer, Affinia Therapeutics
120C
Nov 1216:10
Conference pass
Revolutionizing Cell Therapy Discovery with TROVO Fluidics-free Analysis & Isolation Platform
Start-up Pitch
Dong Wang, CEO, Enrich Biosystems Inc.
Seminar Theatre, Expo Floor
Nov 1216:25
Conference pass
Topic TBC
Start-up Pitch
Samantha Dowse, Principal Consultant/ Director, GreyRigge Associates Limited
Seminar Theatre, Expo Floor
Nov 1216:39
Conference pass
Chair: Ruud Hulspas, Technical Director Process Development, Dana Farber Cancer Institute
Track 1: Cell Therapy
Ruud Hulspas, Technical Director Process Development, Dana-Farber Cancer Institute
Keynote Theatre
Nov 1216:39
Conference pass
Chair: Betsy Lahue, Co-Founder & CEO, Alkemi
Track 3: Evidence, Pricing & Access
120A
Nov 1216:39
Conference pass
Chair: Lore Gruenbaum, Vice President, Therapy Acceleration Program, Leukemia and Lymphoma Society
Track 4: Gene Modified Cell Therapy
120B
Nov 1216:39
Conference pass
Chair: Chris Stevens, EVP, Chief Patient Supply Officer, Spark Therapeutics, Inc.
Track 5: Gene Therapy
120C
Nov 1216:39
Conference pass
Chair: Patrick Hanley, Chief and Director of Cell Therapy Program, Children’s National Hospital (Confirmed)
Track 6: Cell Therapy Manufacture (Sponsored by Terumo BCT)
Patrick Hanley, Chief, Children's National Medical Center
121A
Nov 1216:39
Conference pass
Chair: Seema Bhatlekar, Senior Scientist, Gene Therapy Process Development, Johnson & Johnson Innovative Medicine
Track 7: Viral Vector Manufacture
Seema Bhatlekar, Senior Scientist, Gene Therapy Process Development, Johnson & Johnson Innovative Medicine
121 B
Nov 1216:39
Conference pass
Chair: Yossi Schwartz, Director, Transfusion Services, Moffitt Cancer Center
Track 8: Supply Chain & Logistics
Yossi Schwartz, Director, Transfusion Services, Moffitt Cancer Center
121 C
Nov 1216:40
Conference pass
Patient phenotype and Mesenchymal stem cell-based therapies
Track 1: Cell Therapy
Daniel Weiss, Professor, University of Vermont
Keynote Theatre
Nov 1216:40
Conference pass
CRISPR-directed gene editing for solid tumors; a patient centric approach
Track 2: Innovation Showcase
Seminar Theatre, Expo Floor
Nov 1216:40
Conference pass
Brazilian CAR-T Landscape and Joint Initiatives
Track 3: Evidence, Pricing & Access
120A
Nov 1216:40
Conference pass
Targeting of HLA-G positive tumors with cytotoxic immune cells engineered with a Chimeric ILT-Receptor
Track 4: Gene Modified Cell Therapy
120B
Nov 1216:40
Conference pass
BridgeBio Case Study
Track 5: Gene Therapy
Clayton Beard, CSO and Site Head, BridgeBio Gene Therapy
120C
Nov 1216:40
Conference pass
Innovation in cell therapy manufacturing
Track 6: Cell Therapy Manufacture (Sponsored by Terumo BCT)
Nelly Viseux, SVP, Regeneron Cell Medicines
121A
Nov 1216:40
Conference pass
Efficient and precise engineering of next-gen cell therapy
Track 7: Viral Vector Manufacture
121 B
Nov 1216:40
Conference pass
Off-site Cryogenic Storage and Distribution of Clinical Product to Improve Program Efficiency
Track 8: Supply Chain & Logistics
Michael Francis, Sr Scientist, Manufacturing, Cellenkos
121 C
Nov 1217:00
Conference pass
Harnessing innovative technology to support targeted T-cell therapies
Track 1: Cell Therapy
Dan Bednarik, Chief Technology Officer, Black Canyon Bio
Keynote Theatre
Nov 1217:00
Conference pass
Likarda
Track 2: Innovation Showcase
Stella Vnook, CEO, Likarda Llc
Seminar Theatre, Expo Floor
Nov 1217:00
Conference pass
Overcoming Market Access Barriers Through Provider Partnerships
Track 3: Evidence, Pricing & Access
Emily Diehl, Pharmacy Executive Director, Vizient, Inc.
Mary Tamargo, Strategy and Emerging Mar, Vizient
120A
Nov 1217:00
Conference pass
In vivo programming of immune cells for cancer therapy
Track 4: Gene Modified Cell Therapy
120B
Nov 1217:00
Conference pass
Gene Therapy for Osteoarthritis, A Major Prevalent Indication
Track 5: Gene Therapy
120C
Nov 1217:00
Conference pass
Karyotyping and FISH for the characterization of cell & gene therapy products - A decade of GMP experience
Track 6: Cell Therapy Manufacture (Sponsored by Terumo BCT)
Vasileios Georgakakos, Cytogenetics Manager, Clean Cells
121A
Nov 1217:00
Conference pass
Viral vector DNA integration: Mechanisms and consequences
Track 7: Viral Vector Manufacture
121 B
Nov 1217:00
Conference pass
Non-viral delivery of stably integrating DNA for in vivo CAR-T TCR therapy
Track 8: Supply Chain & Logistics
121 C
Nov 1217:20
Conference pass
Mesenchymal stromal cells: a novel approach to type 1 diabetes treatment
Track 1: Cell Therapy
Keynote Theatre
Nov 1217:20
Conference pass
Panel: Partnering and Investment in Biotech
Track 2: Innovation Showcase
Moderator: Sven Kili, CDO, CCRM
Amanda Placone, Senior Director, Eli Lilly and Company
Jeffrey Walsh, CEO, Nvelop Therapeutics
Faizzan Ahmad, CEO, Cure8bio
Dave Greenwald, VP, Business Development, Deerfield Management
Seminar Theatre, Expo Floor
Nov 1217:20
Conference pass
Innovative payment models for gene therapies
Track 3: Evidence, Pricing & Access
Kelly Kilpatrick, Senior Vice President & Head of US Commercial Ocular Gene Therapy, Spark Therapeutics
120A
Nov 1217:20
Conference pass
Genomic Safety in Allogenic Cell Therapies
Track 4: Gene Modified Cell Therapy
Parimal Pande, Associate Scientific Director, Johnson & Johnson
120B
Nov 1217:20
Conference pass
Panel: Broader Applications for Gene Therapies
Track 5: Gene Therapy
Moderator: Daniel Dornbusch, CEO, Excision Biotherapeutics
Sarah Thomas, VP Quality, REGENXBIO
Darin Curtiss, Global VP Clinical Development, Beacon Therapeutics
120C
Nov 1217:20
Conference pass
Point-of-care manufacturing
Track 6: Cell Therapy Manufacture (Sponsored by Terumo BCT)
Moderator: Patrick Hanley, Chief, Children's National Medical Center
Amanda Conerty, Executive Director, Artiva Biotherapeutics
Tim Wiltshire, Section Director, IMPACT Lab, Mayo Clinic
121A
Nov 1217:20
Conference pass
Streamlining process development
Track 7: Viral Vector Manufacture
Moderator: Frederick Porter, CTO, Taysha Gene Therapies
Seema Bhatlekar, Senior Scientist, Gene Therapy Process Development, Johnson & Johnson Innovative Medicine
Matt Edwards, Senior Director, Head of Process Science, Affinia Therapeutics
121 B
Nov 1217:20
Conference pass
Building your supply chain from scratch
Track 8: Supply Chain & Logistics
Moderator: Lior Raviv (ליאור רביב), CTO, Pluri
Michael Francis, Sr Scientist, Manufacturing, Cellenkos
Nadia Milne, Associate Director, Johnson and Johnson Innovative Medicine
121 C
Nov 1217:40
Conference pass
Developing canine immunotherapies to fully leverage comparative oncology and inform human clinical trials
Track 1: Cell Therapy
Don Siegel, Professor, University of Pennsylvania School Of Medicine
Keynote Theatre
Nov 1217:40
Conference pass
Fireside Chat: Patient access in light of safety updates
Track 3: Evidence, Pricing & Access
Moderator: Susan Brisendine, Director, Patient Advocacy, Bluebird Bio
120A
Nov 1217:40
Conference pass
New horizons: CAR T therapy beyond cancer
Track 4: Gene Modified Cell Therapy
Daniel Baker, PhD Candidate, University of Pennsylvania School Of Medicine
120B
Create your personal agenda –check the favourite icon
Nov 139:00
Conference pass
Opening Remarks: Miguel Forte, CEO, Kiji Therapeutics, President, ISCT
Keynotes
Miguel Forte, President Elect, ISCT, Partner, Kiji Tx
Keynote Theatre
Nov 139:05
Conference pass
Enhancing Potency, Access, and Delivery of CAR T Cell Therapies
Keynotes
Keynote Theatre
Nov 139:25
Conference pass
Keynote Presentation: Details TBC
Keynotes
Ryan Crisman, Co Founder and Chief Technology Officer, Umoja Biopharma
Keynote Theatre
Nov 139:45
Conference pass
Maintaining momentum of commercial therapies to ensure global patient access
Keynotes
Moderator: Miguel Forte, President Elect, ISCT, Partner, Kiji Tx
Sarah Creviston, Global Vice President, Patient Advocacy, Public Affairs and Policy, Novartis Gene Therapies
Michela Zuccolo, Gene Therapy and Rare Strategy, Roche
Keynote Theatre
Nov 1311:09
Conference pass
Chair: Prachi Narayan, Global QC and Clinical Science, Iovance
Track 1: Cell Therapy
Prachi Narayan, Global QC and Clinical Science, Iovance Biotherapeutics
Keynote Theatre
Nov 1311:09
Conference pass
Chair: Robert Bitterman, President and CEO, Phio Pharmaceuticals Corp.
Track 2: Innovation Showcase
Robert Bitterman, President and CEO, Phio Pharmaceuticals Corp.
Seminar Theatre, Expo Floor
Nov 1311:09
Conference pass
Chair: Roland Kolbeck, Chief Scientific Officer, Spirovant Sciences
Track 5: Gene Therapy
Roland Kolbeck, CSO, Spirovant Sciences
120C
Nov 1311:09
Conference pass
Chair: Prateek Tripathi, Senior Expert, Novartis Gene Therapies
Track 6: Cell Therapy Manufacture (Sponsored by Terumo BCT)
Prateek Tripathi, Senior Expert, Novartis Gene Therapies
121A
Nov 1311:09
Conference pass
Chair: Snehal Naik, Head of Regulatory Policy, Spark Therapeutics
Track 9: Regulatory Affairs & Policy
Snehal Naik, Head of Regulatory Policy, Spark Therapeutics
120A
Nov 1311:09
Conference pass
Chair: Albert Ribickas, Assistant Director of Cell Therapy Facility (CTF) Operations, Moffitt Cancer Center
Track 11: Patient Delivery
Albert Ribickas, BMT Manager, Moffitt Cancer Center
121 C
Nov 1311:10
Conference pass
Promises and Challenges of PSC-Derived ProtoNK Cell Therapies
Track 1: Cell Therapy
Allen Feng, Founder, CSO, HebeCell Corporation
Keynote Theatre
Nov 1311:10
Conference pass
Development of human-based microphysiological models for disease modeling and therapeutics testing
Track 2: Innovation Showcase
Seminar Theatre, Expo Floor
Nov 1311:10
Conference pass
The Development of DB-OTO: a gene therapy for otoferlin-related hearing loss
Track 5: Gene Therapy
Meghan Drummond, Director, Auditory Sciences, Regeneron
120C
Nov 1311:10
Conference pass
Analytical development for cell & gene therapies
Track 6: Cell Therapy Manufacture (Sponsored by Terumo BCT)
Prateek Tripathi, Senior Expert, Novartis Gene Therapies
121A
Nov 1311:10
Conference pass
Topic TBC
Track 7: Viral Vector Manufacture
Michael DiBiasio-White, Head of Process Development and Manufacturing Innovations-Associate Director, Affinia Therapeutics
121 B
Nov 1311:10
Conference pass
The Importance of Interacting with Regulators
Track 9: Regulatory Affairs & Policy
Margareth Jorvid, Head of Regulatory Affairs, Ilya Pharma
120A
Nov 1311:10
Conference pass
Rilparencel (Renal Autologous Cell Therapy) for Treatment of Chronic Kidney Disease with Type 2 Diabetes: Clinical Trial Design Considerations and Phase 2 Data Results
Track 10: Clinical Trials & Development
Joseph Stavas, Senior VP, ProKidney
120B
Nov 1311:10
Conference pass
Challenges in Outpatient Treatment of CAR-T patients
Track 11: Patient Delivery
David Porter, Director, University of Pennsylvania
121 C
Nov 1311:30
Conference pass
Harnessing the Potential of the Incubator of Life: multipotent amnion epithelial cells as Immunosuppression-free ATMP
Track 1: Cell Therapy
Roberto Gramignoli, Director, Cell Therapy Unit, Karolinska Institutet
Keynote Theatre
Nov 1311:30
Conference pass
Promotor targeting for clinical gene knockdown - a case study in severe congenital neutropenia
Track 2: Innovation Showcase
Julia Skokowa, Head of Translational Oncology, University Hospital Tübingen
Seminar Theatre, Expo Floor
Nov 1311:30
Conference pass
Retinal Gene Therapy: from Gene specific to gene agnostic approaches
Track 5: Gene Therapy
Daniel Chung, CSO, SparingVision
120C
Nov 1311:30
Conference pass
Akadeum
Track 6: Cell Therapy Manufacture (Sponsored by Terumo BCT)
William Lloyd, Senior Director, R&D, Akadeum
121A
Nov 1311:30
Conference pass
Navigating Regulatory Challenges in Early-Stage Cell Therapy Manufacturing: A Strategic Compliance Perspective
Track 9: Regulatory Affairs & Policy
120A
Nov 1311:30
Conference pass
Common CMC Hurdles during IND Submission
Track 10: Clinical Trials & Development
Patrick Hanley, Chief, Children's National Medical Center
120B
Nov 1311:30
Conference pass
Circle of Care -the impact of nonprofit organizations from research to patient access’
Track 11: Patient Delivery
Bethany Lilly, Executive Director Public Policy, Govt Affairs & Regulatory, Leukemia & Lymphoma Society
Leah Szumita, Director, Clinical Trial Support Center, The Leukemia & Lymphoma Society
Bryon Daily, Senior Manager, Patient & Professional Programs, The Leukemia & Lymphoma Society
121 C
Nov 1311:50
Conference pass
Panel Discussion: Autologous vs Allogenic
Track 1: Cell Therapy
Moderator: John Sholar, Chief Executive Officer, jCyte Inc
Lavanya Peddada, Sr Dir., Process Development, Vittoria Biotherapeutics
Tomer Bronshtein, Vice President of Innovation and Corporate Development, Bonus Biogroup
Daniel Weiss, Professor, University of Vermont
Keynote Theatre
Nov 1311:50
Conference pass
Next-generation precise CRISPR gene editing with chemically ligated guide RNAs
Track 2: Innovation Showcase
Minghong Zhong, CEO, GeneLancet Biosciences, Inc.
Seminar Theatre, Expo Floor
Nov 1311:50
Conference pass
Safety in gene editing
Track 5: Gene Therapy
Moderator: Khandan Baradaran, Ph.D., SVP Regulatory and Quality, Nanoscope Therapeutics
Hugh Gannon, Associate Director, KSQ Therapeutics, Inc.
120C
Nov 1311:50
Conference pass
Staying ahead of the game: scaling up and meeting commercial demand
Track 6: Cell Therapy Manufacture (Sponsored by Terumo BCT)
Moderator: Elena Peletskaya, Senior Scientific Director, Bristol-Myers Squibb
Stephen Sullivan, COO, iPSirius
Allen Horton, Head of Extl Manufacturing, Beam Therapeutics
121A
Nov 1311:50
Conference pass
Panel: Post Market Surveillance and Long-term follow up: How do we make sure the needs for patients are met?
Track 9: Regulatory Affairs & Policy
Samarendra Mohanty, Founder-President, Chief Scientific Officer, Nanoscope Therapeutics
120A
Nov 1311:50
Conference pass
Importance of Diagnostic Development in Cell and Gene Therapy Product Development
Track 10: Clinical Trials & Development
Moderator: Doug Rains, CSO, Quantigen Biosciences
Pratima Cherukuri, CSO, Genezen
120B
Nov 1313:29
Conference pass
Chair: Susan Nichols, CEO, Propel Biosciences
Track 2: Innovation Showcase
Susan B Nichols, Chairwoman, Propel Biosciences
Seminar Theatre, Expo Floor
Nov 1313:29
Conference pass
Chair: Lavanya Peddada Senior Director, Process Development, Vittoria Biotherapeutics
Track 6: Cell Therapy Manufacture (Sponsored by Terumo BCT)
Lavanya Peddada, Sr Dir., Process Development, Vittoria Biotherapeutics
121A
Nov 1313:29
Conference pass
Chair: Angela Justice, Independent, Former Chief People Officer, TCR2 Therapeutics
Track 10: Clinical Trials & Development
ANGELA JUSTICE, Chief People Officer, Justice Group Advisors
120B
Nov 1313:30
Conference pass
Generation of immune effector cells from pooled donor cord blood CD34+ cells
Track 1: Cell Therapy
Colleen Delaney, Founder, CSO, Deverra Therapeutics, Inc.
Keynote Theatre
Nov 1313:30
Conference pass
Don’t Just Survive, Thrive: How to Build Resilience after a Setback
Track 2: Innovation Showcase
ANGELA JUSTICE, Chief People Officer, Justice Group Advisors
Seminar Theatre, Expo Floor
Nov 1313:30
Conference pass
Gene Therapy for Cystic Fibrosis
Track 5: Gene Therapy
Roland Kolbeck, CSO, Spirovant Sciences
120C
Nov 1313:30
Conference pass
Standardization of analytical development to accelerate the development of cell and gene therapies
Track 6: Cell Therapy Manufacture (Sponsored by Terumo BCT)
Sumona (Fed) Sarkar, Biomedical Engineer, NIST USA
121A
Nov 1313:30
Conference pass
The Importance of Newborn Screening in the Era of Cell and Gene Therapies
Track 9: Regulatory Affairs & Policy
Dave Greenwald, VP, Business Development, Deerfield Management
120A
Nov 1313:30
Conference pass
Expanding opportunities for autologous cell therapies in solid tumors
Track 10: Clinical Trials & Development
120B
Nov 1313:30
Conference pass
The clinical perspective: laying the foundation for initial and ongoing care
Track 11: Patient Delivery
Albert Ribickas, BMT Manager, Moffitt Cancer Center
121 C
Nov 1313:50
Conference pass
Treating neurologic conditions in children with cord blood and cord tissue derived therapies
Track 1: Cell Therapy
Joanne Kurtzberg, Professor Of Pediatrics, Duke University Medical Center
Keynote Theatre
Nov 1313:50
Conference pass
New formulation for biodegradable lipbaes for local delivery
Track 5: Gene Therapy
120C
Nov 1313:50
Conference pass
What Goes in Must Come Out: Considerations for Selecting Starting and Ancillary Materials in Cell and Gene Therapy Clinical Manufacturing
Track 10: Clinical Trials & Development
Lara Silverman, VP, CMC/Clinical Ops, Coeptis and LIS BioConsulting
120B
Nov 1314:10
Conference pass
Cord Blood-Derived T-Regulatory Cells
Track 1: Cell Therapy
Michael Francis, Sr Scientist, Manufacturing, Cellenkos
Keynote Theatre
Nov 1314:10
Conference pass
Tissue Therapeutics: Unlocking the value of cell therapies with biomaterials
Track 2: Innovation Showcase
Caralynn Collens, CEO, Dimension Inx
Seminar Theatre, Expo Floor
Nov 1314:10
Conference pass
Challenge and opportunities of nonviral delivery of therapeutic molecules
Track 5: Gene Therapy
Zhenghong Gao, Head of Non-Viral Delivery, Asklepios BioPharmaceutical, Inc.
120C
Nov 1314:10
Conference pass
Manufacturing and Testing of Autologous iPSC-derived Cell Therapies
Track 6: Cell Therapy Manufacture (Sponsored by Terumo BCT)
121A
Nov 1314:10
Conference pass
Regulatory challenges of ATMPs in clinical development
Track 9: Regulatory Affairs & Policy
Matthias Stöcker, Global Regulatory Affairs, Boehringer Ingelheim International GmbH
120A
Nov 1314:10
Conference pass
Revolutionizing Regenerative Medicine: BonoFill™ and MesenCure™ - Pioneering Accessible and Economical Advanced Therapies at Bonus Biogroup
Track 10: Clinical Trials & Development
Tomer Bronshtein, Vice President of Innovation and Corporate Development, Bonus Biogroup
120B
Nov 1314:10
Conference pass
Establishing your network of treatment centers
Track 11: Patient Delivery
121 C
Nov 1314:30
Conference pass
Panel: The future of cord blood derived therapies
Track 1: Cell Therapy
Moderator: Joanne Kurtzberg, Professor Of Pediatrics, Duke University Medical Center
Colleen Delaney, Founder, CSO, Deverra Therapeutics, Inc.
Keynote Theatre
Nov 1314:30
Conference pass
Panel: Company Creation in ATMPs
Track 2: Innovation Showcase
Susan B Nichols, Chairwoman, Propel Biosciences
Caralynn Collens, CEO, Dimension Inx
Frederick Porter, CTO, Taysha Gene Therapies
Victor Dillard, VP, Strategy and Operations, Resolution Therapeutics
Seminar Theatre, Expo Floor
Nov 1314:30
Conference pass
The Challenging Journey to Change the Tropism of AAV Vectors
Track 5: Gene Therapy
Quan Jin, Capsid Engineering Lead, Spark Therapeutics
120C
Nov 1314:30
Conference pass
Improve Bioprocess Freezing Outcomes with Analytics and Testing Services
Track 6: Cell Therapy Manufacture (Sponsored by Terumo BCT)
121A
Nov 1314:30
Conference pass
Panel: First-in-human trials – overcoming regulatory hurdles faced by academics and early-stage companies
Track 9: Regulatory Affairs & Policy
Moderator: Omer Butt, VP, Regulatory Affairs, CytoImmune Therapeutics
Shirley Bartido, Director, Global Regulatory Affairs Oncology Cell Therapy, Takeda
Viera Muzithras, VP, Regulatory Affairs, Be Biopharma
Snehal Naik, Head of Regulatory Policy, Spark Therapeutics
Lara Silverman, VP, CMC/Clinical Ops, Coeptis and LIS BioConsulting
120A
Nov 1314:30
Conference pass
Panel: Considerations for Clinical Trial Design for Cell and Gene Therapies
Track 10: Clinical Trials & Development
Moderator: Daniel Dornbusch, CEO, Excision Biotherapeutics
Amy House, Head of Portfolio Strategy, Beacon Therapeutics
Kate Rochlin, COO, in8bio
Joseph Stavas, Senior VP, ProKidney
Leslie Meltzer, CMO, Orchard Therapeutics
120B
Nov 1314:30
Conference pass
Improving Access to Cell and Gene Therapies
Track 11: Patient Delivery
Robert Richards, Corporate Director, University of Pennsylvania Health System
121 C
Nov 1314:50
Conference pass
Delivery of RNA Gene Writing Systems to Liver and Beyond
Track 5: Gene Therapy
120C
Nov 1314:50
Conference pass
Apheresis Collections: Advances in Managing Patient Material Is Harmonization Needed- Sponsor Perspective
Track 6: Cell Therapy Manufacture (Sponsored by Terumo BCT)
Lizette Caballero, Associate Director, Johnson & Johnson Pharmaceutical R&D
121A
Nov 1314:50
Conference pass
Establishing a new commercialization pathway for ultra-rare disease treatments: Promising science for patients
Track 11: Patient Delivery
Craig Martin, Founder, CEO, Orphan Therapeutics Accelerator
121 C
Nov 1315:39
Conference pass
Chair: John Sholar, Chief Executive Officer, jCyte Inc
Track 1: Cell Therapy
John Sholar, Chief Executive Officer, jCyte Inc
Keynote Theatre
Nov 1315:39
Conference pass
Chair: Daniel Saragnese, CEO and Co-founder, SereNeuro Therapeutics, Inc.
Track 2: Innovation Showcase
Seminar Theatre, Expo Floor
Nov 1315:39
Conference pass
Chair: Shahrooz Rabizadeh, CEO & Co-Founder, Sagittarius Bio, Inc
Track 5: Gene Therapy
Shahrooz Rabizadeh, CEO & Co-Founder, Sagittarius Bio, Inc
120C
Nov 1315:39
Conference pass
Chair: Lavanya Peddada Senior Director, Process Development, Vittoria Biotherapeutics
Track 6: Cell Therapy Manufacture (Sponsored by Terumo BCT)
Lavanya Peddada, Sr Dir., Process Development, Vittoria Biotherapeutics
121A
Nov 1315:39
Conference pass
Chair: Khandan Baradaran, SVP Regulatory and Quality, Nanoscope Therapeutics
Track 9: Regulatory Affairs & Policy
Khandan Baradaran, Ph.D., SVP Regulatory and Quality, Nanoscope Therapeutics
120A
Nov 1315:39
Conference pass
Chair: Dana Silverbush, Assistant Professor of Cancer Biology, University of Pennsylvania
Track 10: Clinical Trials & Development
Dana Silverbush, Assistant Professor of Cancer Biology, University of Pennsylvania
120B
Nov 1315:39
Conference pass
Chair: Rosanna Ferrante, Head of Strategy, Insights, Analytics and Operations, Bluebird Bio
Track 11: Patient Delivery
121 C
Nov 1315:40
Conference pass
Advancing 3D cell therapy for Parkinson’s Disease
Track 1: Cell Therapy
Keynote Theatre
Nov 1315:40
Conference pass
The latest in non-addictive pain therapies
Track 2: Innovation Showcase
Seminar Theatre, Expo Floor
Nov 1315:40
Conference pass
Immune responses to AAV Gene Therapies
Track 5: Gene Therapy
Klaudia Kuranda, Head of Immunology, Indpendent
120C
Nov 1315:40
Conference pass
Ashley Angell Krull, Associate Director, Cell Therapy Manufacturing and Engineering, The Ohio State University Wexner Medical Center
Track 6: Cell Therapy Manufacture (Sponsored by Terumo BCT)
Ashley Krull, Associate Director, The Ohio State University Wexner Medical Center
121A
Nov 1315:40
Conference pass
IND preparedness for cell & gene therapies: Overcoming regulatory challenges
Track 9: Regulatory Affairs & Policy
Shirley Bartido, Director, Global Regulatory Affairs Oncology Cell Therapy, Takeda
120A
Nov 1315:40
Conference pass
Investigating CAR T Resistance in Glioblastoma: Single-Cell Analysis of Longitudinal CSF
Track 10: Clinical Trials & Development
Dana Silverbush, Assistant Professor of Cancer Biology, University of Pennsylvania
120B
Nov 1316:00
Conference pass
Targeting cancer with a new comprehensive stem cell-based immunotherapy, IPVAC
Track 1: Cell Therapy
Stephen Sullivan, COO, iPSirius
Keynote Theatre
Nov 1316:00
Conference pass
INTASYL self-delivering siRNA for adoptive cell therapy applications
Track 2: Innovation Showcase
Melissa Maxwell, Director of Research and Program Management, Phio Pharmaceuticals Corp.
Seminar Theatre, Expo Floor
Nov 1316:00
Conference pass
Gene therapy for cancer
Track 5: Gene Therapy
Shahrooz Rabizadeh, CEO & Co-Founder, Sagittarius Bio, Inc
120C
Nov 1316:00
Conference pass
Selecting specific T-Cells in cell therapy manufacturing
Track 6: Cell Therapy Manufacture (Sponsored by Terumo BCT)
Ruud Hulspas, Technical Director Process Development, Dana-Farber Cancer Institute
121A
Nov 1316:00
Conference pass
Addressing off-target / off-tumor toxicity of existing T cell based therapies with a new generation of engineered binders
Track 10: Clinical Trials & Development
Nikolaos Sgourakis, Associate Professor of Biochemistry and Biophysics, Perelman School of Medicine at the University of Pennsylvania
120B
last published: 01/Oct/24 11:05 GMT
Get Involved with the Advanced Therapies Congress
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events